FluoroPharma Medical's CEO and Chairman, Thijs Spoor, to Present at Taglich Brothers 10th Annual Small Cap Equity Conference on May 7th

Mr. Spoor to Provide Business and Portfolio Updates

Marketwired

MONTCLAIR, NJ--(Marketwired - April 30, 2013) -  FluoroPharma Medical, Inc. (FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today announced that Thijs Spoor, Chairman & CEO of FluoroPharma Medical, will present at the Taglich Brothers 10th Annual Small Cap Conference at the New York Athletic Club in New York City on Tuesday, May 7, 2013.

Mr. Spoor will be presenting from 9:30 to 9:55AM in the 9thFloor Lounge. A Q&A session will immediately follow the presentation from 10:00 to 10:30AM.

Interested investors can access the live webcast of the presentation by going to FluoroPharma's web site, www.fluoropharma.com and clicking the Investor Relations link. The webcast will remain on the FluoroPharma web site for 90 days following the event. The webcast can also be accessed via the Taglich Brothers website, www.taglichbrothers.com where a link to the webcast can be found on the main home page. 

A copy of the presentation materials will only be available on the FluoroPharma website at www.fluoropharma.com

FluoroPharma recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access.

About FluoroPharma Medical

FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The Company has licensed technology from the Massachusetts General Hospital in Boston.

The Company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.

FluoroPharma's initial focus is the development of breakthrough positron emission tomography (PET) imaging agents and is advancing two products in clinical trials for assessment of acute and chronic forms of coronary disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image Alzheimer's disease and agents that could potentially be used for imaging specific cancers.

In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia, Finland, Portugal, Ireland and Mexico.

For more information on the Company, please visit: www.fluoropharma.com 

Forward-Looking Statements 

Except for historical information contained herein, the statements in this release are forward-looking. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
CONTACT:
Media: 
Carol J. Perlman
FluoroPharma Medical, Inc.
cperlman@fluoropharma.com
Phone: 917-592-9260

Investor Relations: 
Richard Moyer
Cameron Associates, Inc.
Richard@cameronassoc.com
Phone: 212-554-5466
View Comments (0)